Successful treatment of poor prognostic patients with advanced prostatic carcinoma with the association of diethylstilbestrol and cyclophosphamide.
A combination of hormonal therapy and chemotherapy (diethyl-estilbestrol or orchiectomy plus cyclophosphamide) was administered to 14 patients with histologic proof of untreated stage D prostatic adenocarcinoma with poor prognosis. Objective responses were obtained in 11 out of the 14 patients (78%), two of which were considered as complete regressions (14%). Response duration lasted for a mean of 9.5 months and the survival reached a mean of 14 months. The authors feel that is worth-while to treat very advanced cases of prostatic carcinoma with hormonal therapy and chemotherapy association.